Hardman Johnston Global Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Hardman Johnston Global Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$83.81 - $99.0 $414,859 - $490,050	-4,950 Reduced 2.9%	165,610 $14.5 Million
Q4 2023 Jan 29, 2024	SELL	$76.22 - $98.51 $119,665 - $154,660	-1,570 Reduced 0.91%	170,560 $16.4 Million
Q3 2023 Oct 20, 2023	SELL	$85.07 - $94.48 $119,097 - $132,272	-1,400 Reduced 0.81%	172,130 $15.2 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $7.12 Million - $8.24 Million	82,130 Added 89.86%	173,530 $15 Million
Q1 2023 May 05, 2023	BUY	$87.74 - $117.27 $8.02 Million - $10.7 Million	91,400 New	91,400 $8.89 Million

638

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Hardman Johnston Global Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Hardman Johnston Global Advisors LLC with notifications on news.